Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis

Nephrology Dialysis Transplantation

Volumn 19, Issue 6, 2004, Pages 1559-1563

  Aggarwal, Atul ^a,b   Whitaker, Deborah A ^a   Rimmer, Jeffrey M ^a   Solomon, Richard J ^a   Gennari, F John ^a   Sobel, Burton E ^a   Schneider, David J ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Enoxaparin; Kidney; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PADGEM PROTEIN; WARFARIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTICOAGULATION; ARTERIAL BLOOD; ARTICLE; ATTENUATION; BLOOD SAMPLING; CELL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HEART DISEASE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTE ACTIVATION;

AGED; ANTICOAGULANTS; BLOOD PLATELETS; ENOXAPARIN; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HEPARIN; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PROTEIN BINDING; RENAL DIALYSIS;

EID: 2942700120     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh209     Document Type: Article

References (20)

1. Renal Data System. USRDS 1997 Annual Data Report. NIH Publication no. 97-3176. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 1997: 91-101
2. Sarnak MI. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41 [Suppl 5]: S11-S17
3. Rubenstein MH, Harrell LC, Sheynberg BV et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000; 102: 2966-2972
4. Kabbani SS, Watkins MW, Ashikaga T et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104: 181-186
5. Aggarwal A, Kabbani SS, Rimmer JM et al. Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease, a potential contributor to cardiovascular risk. Am J Kidney Dis 2002; 40: 315-322
6. Benigni A, Boccardo P, Galbusera M et al. Reversible activation defect of the glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 1993; 22: 668-676
7. Reverter JC, Escolar G, Sanz C et al. Platelet activation during hemodialysis measured through exposure of p-selectin: analysis by flow cytometric and ultrastructural techniques. J Lab Clin Med 1994; 124: 79-85
8. Schneider DJ, Tracy PB, Mann KG et al. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997; 96: 2877-2883
9. Aggarwal A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 2002; 13: 161-165
10. Saltissi D, Morgan C, Westhuyzen J, Healy H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 1999; 14: 2698-2703
11. Polkinghorne KR, McMahon LP, Becker GJ. Pharmacokinetic studies of dalteparin Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 990-995
12. Schneider DJ, Taatjes DJ, Howard DB et al. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk. J Am Coll Cardiol 1999; 33: 261-266
13. Xia Z, Wong T, Liu Q et al. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantification of binding to activated platelets and platelet aggregation. Br J Haematol 1996; 93: 204-214
14. Holme PA, Orvim U, Hamers MJ et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997; 17: 646-653
15. 2+-ATPase inhibitors. Biochemistry 1995; 34: 11625-11634
16. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-452
17. Anastassiades E, Ireland H, Flynn A, Lane DA, Curtis JR. A low-molecular-weight heparin (KABI 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin. Nephrol Dial Transplant 1990; 5: 135-140
18. Len JG, Chiang SS, Lin SM, Pai JK, Jiang WW. Low molecular weight heparin in hemodialysis patients with a bleeding tendency. Nephron 2000; 86: 499-501
19. Naumnik B, Borawski J, Mysliwiec M. Differential effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study. Nephrol Dial Transplant 2003; 18: 1376-1382
20. Rostand SG, Rutsky EA. Coronary artery disease in end-stage renal disease. In: Heinrich WL, ed. Principles and Practice of Dialysis. Williams and Wilkins, Baltimore, MD; 1994: 181-195